Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 4/2015

01.12.2015 | short review

Soft tissue sarcomas & GIST Insights into subtype-specific therapy concepts: Highlights from ASCO meeting 2015

verfasst von: MD Sophie Schur, MD Prof. Thomas Brodowicz

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten
share
TEILEN

Abstract

Sarcomas are a rare and heterogeneous group of mesenchymal malignancies that have historically been challenging in diagnosis and treatment. In soft tissue sarcomas (STS), the recognition of different histological subtypes has made a dramatic conceptual change leading to histotype-driven targeted therapies. In gastrointestinal stromal tumors (GIST), the most important advance in the past decade was the demonstration that tyrosine kinase inhibitors (TKIs) can durably control disease and lead to remarkable treatment responses. The advent of TKIs has unquestionably changed the overall survival of patients with GIST, not only in the advanced-disease setting but also in individuals with high-risk disease. This review covers the latest clinical study highlights for STS and GIST presented at American Society of Clinical Oncology (ASCO) 2015 meeting, demonstrating the constant progress from conventional chemotherapy to histology-driven therapy approaches.
Literatur
1.
Zurück zum Zitat Group E.S.E.S.N.W. Soft tissue and visceral sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25 Suppl 3:iii102–12. Group E.S.E.S.N.W. Soft tissue and visceral sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25 Suppl 3:iii102–12.
2.
Zurück zum Zitat Eriksson M. Histology-driven chemotherapy of soft-tissue sarcoma. Ann Oncol. 2010;21 Suppl 7:vii270–6. PubMed Eriksson M. Histology-driven chemotherapy of soft-tissue sarcoma. Ann Oncol. 2010;21 Suppl 7:vii270–6. PubMed
3.
Zurück zum Zitat Reichardt P. Soft tissue sarcomas, a look into the future: different treatments for different subtypes. Future Oncol. 2014;10(8 Suppl):s19–27. PubMedCrossRef Reichardt P. Soft tissue sarcomas, a look into the future: different treatments for different subtypes. Future Oncol. 2014;10(8 Suppl):s19–27. PubMedCrossRef
4.
Zurück zum Zitat Group E.S.E.S.N.W. Gastrointestinal stromal tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25 Suppl 3:iii21–6. Group E.S.E.S.N.W. Gastrointestinal stromal tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25 Suppl 3:iii21–6.
5.
Zurück zum Zitat Blay JY, Reichardt P. Advanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendations. Expert Rev Anticancer Ther. 2009;9(6):831–8. PubMedCrossRef Blay JY, Reichardt P. Advanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendations. Expert Rev Anticancer Ther. 2009;9(6):831–8. PubMedCrossRef
6.
Zurück zum Zitat Reichardt P, et al. Adjuvant therapy in primary GIST: state-of-the-art. Ann Oncol. 2012;23(11):2776–81. PubMedCrossRef Reichardt P, et al. Adjuvant therapy in primary GIST: state-of-the-art. Ann Oncol. 2012;23(11):2776–81. PubMedCrossRef
7.
Zurück zum Zitat Tapp WD. A randomized phase Ib/II study evaluating the safety and efficacy of olaratumab (IMC-3G3), a human anti-platelet-derived growth factor α (PDGFRα) monoclonal antibody, with or without doxorubicin (Dox), in advanced soft tissue sarcoma (STS). 2015 ASCO Annual Meeting. 2015. Tapp WD. A randomized phase Ib/II study evaluating the safety and efficacy of olaratumab (IMC-3G3), a human anti-platelet-derived growth factor α (PDGFRα) monoclonal antibody, with or without doxorubicin (Dox), in advanced soft tissue sarcoma (STS). 2015 ASCO Annual Meeting. 2015.
8.
Zurück zum Zitat Mir O, et al. Activity of regorafenib (RE) in leiomyosarcomas (LMS) and other types of soft-tissue sarcomas (OTS): Results of a double-blind, randomized placebo (PL) controlled phase II trial. 2015 ASCO Annual Meeting. 2015. Mir O, et al. Activity of regorafenib (RE) in leiomyosarcomas (LMS) and other types of soft-tissue sarcomas (OTS): Results of a double-blind, randomized placebo (PL) controlled phase II trial. 2015 ASCO Annual Meeting. 2015.
9.
Zurück zum Zitat Kim C, et al. Clinical pattern and implication of PD-L1 expression in soft-tissue sarcoma. ASCO 2015 Annual Meeting. 2015. Kim C, et al. Clinical pattern and implication of PD-L1 expression in soft-tissue sarcoma. ASCO 2015 Annual Meeting. 2015.
10.
Zurück zum Zitat Burgess MA. SARC 028: a phase II study of the anti-PD1 antibody pembrolizumab (P) in patients (Pts) with advanced sarcomas. 2015 ASCO Annual Meeting. 2015. Burgess MA. SARC 028: a phase II study of the anti-PD1 antibody pembrolizumab (P) in patients (Pts) with advanced sarcomas. 2015 ASCO Annual Meeting. 2015.
11.
Zurück zum Zitat Demetri GD. A randomized phase III study of trabectedin (T) or dacarbazine (D) for the treatment of patients (pts) with advanced liposarcoma (LPS) or leiomyosarcoma (LMS). 2015 ASCO Annual Meeting. 2015. Demetri GD. A randomized phase III study of trabectedin (T) or dacarbazine (D) for the treatment of patients (pts) with advanced liposarcoma (LPS) or leiomyosarcoma (LMS). 2015 ASCO Annual Meeting. 2015.
12.
Zurück zum Zitat Seddon BM. GeDDiS: a prospective randomised controlled phase III trial of gemcitabine and docetaxel compared with doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft tissue sarcomas (EudraCT 2009-014907-29). 2015 ASCO Annual Meeting. 2015. Seddon BM. GeDDiS: a prospective randomised controlled phase III trial of gemcitabine and docetaxel compared with doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft tissue sarcomas (EudraCT 2009-014907-29). 2015 ASCO Annual Meeting. 2015.
13.
Zurück zum Zitat Schoeffski P. Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI). 2015 ASCO Annual Meeting. 2015. Schoeffski P. Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI). 2015 ASCO Annual Meeting. 2015.
14.
Zurück zum Zitat Joensuu H. Three vs. 1 year of adjuvant imatinib (IM) for operable high-risk GIST: The second planned analysis of the randomized SSGXVIII/AIO trial. 2015 ASCO Annual Meeting. 2015. Joensuu H. Three vs. 1 year of adjuvant imatinib (IM) for operable high-risk GIST: The second planned analysis of the randomized SSGXVIII/AIO trial. 2015 ASCO Annual Meeting. 2015.
15.
Zurück zum Zitat Chandrajit PR.-. Adjuvant imatinib (IM) for patients (pts) with primary gastrointestinal stromal tumor (GIST) at significant risk of recurrence: PERSIST-5 planned 3-year interim analysis. 2015 ASCO Annual Meeting. 2015. Chandrajit PR.-. Adjuvant imatinib (IM) for patients (pts) with primary gastrointestinal stromal tumor (GIST) at significant risk of recurrence: PERSIST-5 planned 3-year interim analysis. 2015 ASCO Annual Meeting. 2015.
16.
Zurück zum Zitat Blay JY. Final results of the multicenter randomized phase II PAZOGIST trial evaluating the efficacy of pazopanib (P) plus best supportive care (BSC) vs BSC alone in resistant unresectable metastatic and/or locally advanced gastrointestinal stromal tumors (GIST). 2015 ASCO Annual Meeting. 2015. Blay JY. Final results of the multicenter randomized phase II PAZOGIST trial evaluating the efficacy of pazopanib (P) plus best supportive care (BSC) vs BSC alone in resistant unresectable metastatic and/or locally advanced gastrointestinal stromal tumors (GIST). 2015 ASCO Annual Meeting. 2015.
17.
Zurück zum Zitat Chi P. A phase Ib/II study of MEK162 (binimetinib [BINI]) in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST). 2015 ASCO Annual Meeting. 2015. Chi P. A phase Ib/II study of MEK162 (binimetinib [BINI]) in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST). 2015 ASCO Annual Meeting. 2015.
Metadaten
Titel
Soft tissue sarcomas & GIST Insights into subtype-specific therapy concepts: Highlights from ASCO meeting 2015
verfasst von
MD Sophie Schur
MD Prof. Thomas Brodowicz
Publikationsdatum
01.12.2015
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 4/2015
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-015-0233-5